# Nexpoint Diversified Real Estate Trust: financial statements, quarterly

NXDT · NYSE · CIK 1356115 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nxdt.md) · [Financials](/companies/nxdt/financials.md) · [Filings](/companies/nxdt/filings.md) · [Insiders](/companies/nxdt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nxdt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [12.4](/filings/0001356115-24-000022.md) | [22.2 d](/filings/0001356115-25-000003.md) | [12.8](/filings/0001356115-25-000014.md) | [22.3](/filings/0001356115-25-000021.md) | [22.2](/filings/0001628280-25-052132.md) | [25.9 d](/filings/0001193125-26-133271.md) | [29.1](/filings/0001193125-26-225400.md) | [21.0](/filings/0001193125-26-350420.md) | [17.5](/filings/0001628280-25-052132.md) | [18.4 d](/filings/0001193125-26-133271.md) | [22.9](/filings/0001193125-26-225400.md) | [19.3](/filings/0001193125-26-350420.md) |
| Operating income | $m | [(0.5)](/filings/0001356115-24-000022.md) | [9.7 d](/filings/0001356115-25-000003.md) | [0.3](/filings/0001356115-25-000014.md) | [0.6](/filings/0001356115-25-000021.md) | [(5.9)](/filings/0001628280-25-052132.md) | [0.9 d](/filings/0001193125-26-133271.md) | [5.5](/filings/0001193125-26-225400.md) | [(0.1)](/filings/0001193125-26-350420.md) | [(3.3)](/filings/0001628280-25-052132.md) | [(3.5) d](/filings/0001193125-26-133271.md) | [3.5](/filings/0001193125-26-225400.md) | [2.1](/filings/0001193125-26-350420.md) |
| Interest expense | $m | [4.2](/filings/0001356115-23-000015.md) | [4.5 d](/filings/0001356115-24-000007.md) | [4.5](/filings/0001356115-24-000012.md) | [7.9](/filings/0001356115-24-000016.md) | [8.3](/filings/0001356115-24-000022.md) | [7.7 d](/filings/0001193125-26-133271.md) | [7.3](/filings/0001193125-26-225400.md) | [6.6](/filings/0001193125-26-350420.md) | [6.9](/filings/0001628280-25-052132.md) | [5.8 d](/filings/0001193125-26-133271.md) | [5.7](/filings/0001193125-26-225400.md) | [5.3](/filings/0001193125-26-350420.md) |
| Income tax | $m | [0.3](/filings/0001356115-24-000022.md) | [1.3 d](/filings/0001356115-25-000003.md) | [0.6](/filings/0001356115-25-000014.md) | [0.3](/filings/0001356115-25-000021.md) | [0.7](/filings/0001628280-25-052132.md) | [(0.2) d](/filings/0001193125-26-133271.md) | [1.2](/filings/0001193125-26-225400.md) | [(0.6)](/filings/0001193125-26-350420.md) | [(1.0)](/filings/0001628280-25-052132.md) | [0.3 d](/filings/0001193125-26-133271.md) | [0.9](/filings/0001193125-26-225400.md) | [0.4](/filings/0001193125-26-350420.md) |
| Net income | $m | [(69.1)](/filings/0001356115-24-000022.md) | [(17.0) d](/filings/0001356115-25-000003.md) | [(22.7)](/filings/0001356115-25-000014.md) | [(9.8)](/filings/0001356115-25-000021.md) | [(10.0)](/filings/0001628280-25-052132.md) | [(8.8) d](/filings/0001193125-26-133271.md) | [(34.3)](/filings/0001193125-26-225400.md) | [(45.3)](/filings/0001193125-26-350420.md) | [(13.7)](/filings/0001628280-25-052132.md) | [(36.9) d](/filings/0001193125-26-133271.md) | [(23.0)](/filings/0001193125-26-225400.md) | [0.1](/filings/0001193125-26-350420.md) |
| Diluted EPS | $ per share | [(1.86)](/filings/0001356115-24-000022.md) | not reported | [(0.59)](/filings/0001356115-25-000014.md) | [(0.24)](/filings/0001356115-25-000021.md) | [(0.25)](/filings/0001628280-25-052132.md) | not reported | [(0.80)](/filings/0001193125-26-225400.md) | [(0.99)](/filings/0001193125-26-350420.md) | [(0.29)](/filings/0001628280-25-052132.md) | not reported | [(0.46)](/filings/0001193125-26-225400.md) | [0.00](/filings/0001193125-26-350420.md) |
| Basic EPS | $ per share | [(1.86)](/filings/0001356115-24-000022.md) | not reported | [(0.59)](/filings/0001356115-25-000014.md) | [(0.24)](/filings/0001356115-25-000021.md) | [(0.25)](/filings/0001628280-25-052132.md) | not reported | [(0.80)](/filings/0001193125-26-225400.md) | [(0.99)](/filings/0001193125-26-350420.md) | [(0.29)](/filings/0001628280-25-052132.md) | not reported | [(0.46)](/filings/0001193125-26-225400.md) | [0.00](/filings/0001193125-26-350420.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.7](/filings/0001356115-23-000015.md) | [20.6](/filings/0001356115-25-000003.md) | [20.2](/filings/0001356115-24-000012.md) | [28.4](/filings/0001356115-24-000016.md) | [8.5](/filings/0001356115-24-000022.md) | [8.8](/filings/0001193125-26-133271.md) | [9.5](/filings/0001356115-25-000014.md) | [4.7](/filings/0001356115-25-000021.md) | [5.3](/filings/0001628280-25-052132.md) | [8.2](/filings/0001193125-26-350420.md) | [9.4](/filings/0001193125-26-225400.md) | [11.7](/filings/0001193125-26-350420.md) |
| Total assets | $m | [1,101](/filings/0001356115-23-000015.md) | [1,098](/filings/0001356115-25-000003.md) | [1,075](/filings/0001356115-24-000012.md) | [1,250](/filings/0001356115-24-000016.md) | [1,241](/filings/0001356115-24-000022.md) | [1,225](/filings/0001193125-26-133271.md) | [1,180](/filings/0001356115-25-000014.md) | [1,111](/filings/0001356115-25-000021.md) | [1,107](/filings/0001628280-25-052132.md) | [1,075](/filings/0001193125-26-350420.md) | [1,027](/filings/0001193125-26-225400.md) | [1,039](/filings/0001193125-26-350420.md) |
| Total liabilities | $m | [199](/filings/0001356115-23-000015.md) | [213](/filings/0001356115-25-000003.md) | [212](/filings/0001356115-24-000012.md) | [391](/filings/0001356115-24-000016.md) | [398](/filings/0001356115-24-000022.md) | [391](/filings/0001193125-26-133271.md) | [382](/filings/0001356115-25-000014.md) | [355](/filings/0001356115-25-000021.md) | [357](/filings/0001628280-25-052132.md) | [354](/filings/0001193125-26-350420.md) | [324](/filings/0001193125-26-225400.md) | [324](/filings/0001193125-26-350420.md) |
| Shareholders' equity | $m | [902](/filings/0001356115-23-000015.md) | [885](/filings/0001356115-25-000003.md) | [863](/filings/0001356115-24-000012.md) | [859](/filings/0001628280-25-052132.md) | [843](/filings/0001628280-25-052132.md) | [837](/filings/0001193125-26-133271.md) | [803](/filings/0001356115-25-000014.md) | [753](/filings/0001356115-25-000021.md) | [739](/filings/0001628280-25-052132.md) | [700](/filings/0001193125-26-350420.md) | [675](/filings/0001193125-26-225400.md) | [673](/filings/0001193125-26-350420.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [2,375 d](/filings/0001356115-24-000022.md) | [(5,792) d](/filings/0001356115-25-000003.md) | [(2,555)](/filings/0001356115-25-000014.md) | [(5,492) d](/filings/0001356115-25-000021.md) | [497 d](/filings/0001628280-25-052132.md) | [(4,115) d](/filings/0001193125-26-133271.md) | [7,076](/filings/0001193125-26-225400.md) | [75.0 d](/filings/0001193125-26-350420.md) | [835 d](/filings/0001628280-25-052132.md) | [1,180 d](/filings/0001193125-26-133271.md) | [(498)](/filings/0001193125-26-225400.md) | [(4,633) d](/filings/0001193125-26-350420.md) |
| Dividends paid | $k | [1,219 d](/filings/0001356115-24-000022.md) | [948 d](/filings/0001356115-25-000003.md) | [1,158](/filings/0001356115-25-000014.md) | [1,298 d](/filings/0001356115-25-000021.md) | [1,227 d](/filings/0001628280-25-052132.md) | [1,258 d](/filings/0001193125-26-133271.md) | [1,471](/filings/0001193125-26-225400.md) | [1,544 d](/filings/0001193125-26-350420.md) | [1,423 d](/filings/0001628280-25-052132.md) | [1,572 d](/filings/0001193125-26-133271.md) | [1,817](/filings/0001193125-26-225400.md) | [2,086 d](/filings/0001193125-26-350420.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-133271.md) | [0.0](/filings/0001193125-26-225400.md) | [0.0 d](/filings/0001193125-26-350420.md) | [800 d](/filings/0001628280-25-052132.md) | [1,085 d](/filings/0001193125-26-133271.md) | [2,250](/filings/0001193125-26-225400.md) | [515 d](/filings/0001193125-26-350420.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [37.2](/filings/0001356115-23-000015.md) | [37.2](/filings/0001356115-24-000012.md) | [37.2](/filings/0001356115-24-000016.md) | [37.2](/filings/0001356115-24-000022.md) | [38.6](/filings/0001356115-25-000014.md) | [39.6](/filings/0001356115-25-000021.md) | [40.8](/filings/0001628280-25-052132.md) | [42.9](/filings/0001193125-26-225400.md) | [45.7](/filings/0001193125-26-350420.md) | [47.4](/filings/0001628280-25-052132.md) | [50.1](/filings/0001193125-26-225400.md) | [60.4](/filings/0001193125-26-350420.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 53,106,027 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-350420.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.